None (BMRA) is a publicly traded company. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.
Analysis Summary
None reported revenue of $4.5M in the most recent fiscal year, growing at a 5-year CAGR of -9.2%.
Balance sheet quality for BMRA: current ratio of 1.6, net debt of $1.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.37 |
| Market Cap | $7M |
Financial Health
| Piotroski F-Score | 3 |
| Altman Z-Score | -11.56 |
Price Performance
| 1 month | +48.12% |
| 3 months | +32.40% |
| Year-to-date | -5.95% |
| 1 year | -18.84% |
| 3 years | -73.07% |
| 5 years | -93.63% |
52-Week Range
| 52-week High | $3.21 |
| 52-week Low | $1.45 |
| Avg Volume (90d) | 54K |
Related companies: ALZN · CELZ · HSCS · IINN · LFWD · LUCY · PAVM
More sections of BMRA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks